Selective Peptidomimetic Ligands for MC3R Activation and MC4R Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective melanocortin ligands that can activate the melanocortin-3 receptor (MC3R) while simultaneously blocking the activation of the melanocortin-4 receptor (MC4R, as existing MC4R agonists have off-target effects such as increased blood pressure and erectile activity, limiting their clinical utility in obesity treatment.
Innovation Solution
Development of a compound of formula I, which includes specific alkyl and substituent groups, allowing for selective activation of MC3R and blockade of MC4R, represented by the formula: where R1, R2, R3, and R4 can be H or various alkyl groups optionally substituted with halo, hydroxy, nitro, cyano, and other groups, and A1, A2, A3, and A4 can be cycloalkyl, aryl, or heteroaryl groups, along with their substitutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MC4R agonists are used to treat obesity, then body weight regulation is improved, but off-target effects such as increased blood pressure and erectile activity occur
Solution Approach 1:
The patent segments the melanocortin receptor system by developing compounds that selectively target MC3R while blocking MC4R, rather than using broad-spectrum MC4R agonists. This segmentation allows independent modulation of MC3R (for body weight regulation) without activating MC4R (which causes off-target effects), thereby resolving the contradiction between therapeutic efficacy and harmful side effects
Solution Approach 2:
The invention applies local quality by designing ligands with specific molecular characteristics (substituents at R1-R4 positions and A1-A4 groups) that confer selective affinity for MC3R over MC4R. This localized molecular design ensures the compound interacts specifically with the target receptor subtype, improving body weight regulation while avoiding off-target effects on other melanocortin receptors
2Reliability
If selective melanocortin ligands are developed to activate MC3R and block MC4R, then therapeutic utility for obesity is improved, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters (substituents at R1-R4 positions, A1-A4 aromatic groups, and linker lengths) to optimize the balance between selectivity and complexity. By adjusting these parameters, the invention achieves high therapeutic utility through selective MC3R activation and MC4R blockade while managing compound complexity through structured molecular design
Data Source
AI summary
The invention provides compounds having the general formula I:and salts thereof, wherein the variables R1, R2, R3 and R4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.